Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
TTNP

TTNP - Titan Pharmaceuticals Inc Stock Price, Fair Value and News

6.08USD-0.40 (-6.17%)Delayed as of 17 May 2024, 02:01 pm ET

Market Summary

TTNP
USD6.08-0.40
Delayedas of 17 May 2024, 02:01 pm
-6.17%

TTNP Stock Price

View Fullscreen

TTNP RSI Chart

TTNP Valuation

Market Cap

5.9M

Price/Earnings (Trailing)

-1.2

Price/Sales (Trailing)

32.2

Price/Free Cashflow

-1.02

TTNP Price/Sales (Trailing)

TTNP Profitability

Return on Equity

-81.39%

Return on Assets

-74.54%

Free Cashflow Yield

-98.04%

TTNP Fundamentals

TTNP Revenue

Revenue (TTM)

184.0K

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

TTNP Earnings

Earnings (TTM)

-5.0M

Earnings Growth (Yr)

36.72%

Earnings Growth (Qtr)

32.23%

Breaking Down TTNP Revenue

52 Week Range

6.65
(Low)(High)

Last 7 days

-5.0%

Last 30 days

-10.7%

Last 90 days

-9.0%

Trailing 12 Months

-59.0%

How does TTNP drawdown profile look like?

TTNP Financial Health

Current Ratio

11.83

TTNP Investor Care

Shares Dilution (1Y)

21.77%

Diluted EPS (TTM)

-8.54

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
2023463.5K396.5K304.5K184.0K
20221.0M741.0K572.0K557.5K
20214.4M3.6M2.8M1.5M
20202.8M3.5M3.6M4.8M
20195.5M4.3M3.6M2.6M
20181.2M3.8M4.8M6.6M
201711.4M7.6M3.9M215.0K
2016015.8M15.0M15.1M
20153.6M3.5M2.6M1.7M
20146.2M4.9M3.6M3.6M
201311.0M11.9M12.8M10.5M
20124.4M5.1M5.3M7.1M
20118.9M6.5M5.3M4.1M
201000010.1M
20090000
20080000

Tracking the Latest Insider Buys and Sells of Titan Pharmaceuticals Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Mar 18, 2024
choong choon hau
acquired
-
-
54,132
-
Oct 25, 2023
ben-tzvi avraham
acquired
-
-
16,250
-
Oct 25, 2023
greenberg eric howard
acquired
-
-
16,250
-
Oct 25, 2023
mcmurdo matthew charles
acquired
-
-
16,250
-
Oct 25, 2023
beebe katherine
acquired
-
-
16,250
president and coo
Oct 25, 2023
natan david
acquired
-
-
16,250
-
Jul 26, 2023
chasey peter louis
acquired
-
-
50,000
-
Jul 26, 2023
ben-tzvi avraham
acquired
-
-
50,000
-
Jul 26, 2023
greenberg eric howard
acquired
-
-
50,000
-

1–10 of 26

Which funds bought or sold TTNP recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 15, 2024
STATE STREET CORP
sold off
-100
-15,793
-
-%
May 15, 2024
MORGAN STANLEY
sold off
-100
-1.00
-
-%
May 15, 2024
MORGAN STANLEY
new
-
21.00
21.00
-%
May 15, 2024
BANK OF AMERICA CORP /DE/
sold off
-100
-85.00
-
-%
May 15, 2024
BANK OF AMERICA CORP /DE/
new
-
86.00
86.00
-%
May 15, 2024
Nemes Rush Group LLC
new
-
8.00
8.00
-%
May 15, 2024
Tower Research Capital LLC (TRC)
sold off
-100
-638
-
-%
May 15, 2024
Tower Research Capital LLC (TRC)
new
-
4,633
4,633
-%
May 15, 2024
MILLENNIUM MANAGEMENT LLC
sold off
-100
-6,234
-
-%
May 14, 2024
NewEdge Advisors, LLC
sold off
-100
-2.00
-
-%

1–10 of 42

Are Funds Buying or Selling TTNP?

Are funds buying TTNP calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own TTNP
No. of Funds

Unveiling Titan Pharmaceuticals Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Apr 05, 2024
sire group ltd.
14.1%
150,087
SC 13D/A
Oct 04, 2023
sire group ltd.
16.7%
3,001,757
SC 13D
Jul 21, 2023
choong choon hau
24.95%
3,747,968
SC 13D
Jun 23, 2023
activist investing llc
0%
0
SC 13D/A
Dec 15, 2022
activist investing llc
25.2%
3,690,468
SC 13D/A
Aug 17, 2022
activist investing llc
25.2%
3,690,468
SC 13D/A
Jul 08, 2022
activist investing llc
25.2%
3,690,468
SC 13D/A
Jun 09, 2022
activist investing llc
9.9%
1,441,278
SC 13D/A
Apr 25, 2022
activist investing llc
5.6%
673,211
SC 13D
Feb 14, 2022
l1 capital global opportunities master fund, ltd.
4.99%
494,716
SC 13G/A

Recent SEC filings of Titan Pharmaceuticals Inc

View All Filings
Date Filed Form Type Document
May 15, 2024
10-Q
Quarterly Report
Apr 26, 2024
RW
RW
Apr 05, 2024
SC 13D/A
13D - Major Acquisition
Apr 05, 2024
3
Insider Trading
Apr 05, 2024
3
Insider Trading
Apr 03, 2024
8-K
Current Report
Apr 01, 2024
8-K
Current Report
Apr 01, 2024
10-K
Annual Report
Mar 27, 2024
4
Insider Trading
Mar 21, 2024
8-K
Current Report

Peers (Alternatives to Titan Pharmaceuticals Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
50.9B
6.8B
27.86% 5.69%
-8.52
7.43
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
19.1B
2.0B
3.08% -21.73%
-57.61
9.55
75.20% 68.82%
14.6B
2.5B
-15.33% -16.61%
71.11
5.91
13.74% 186.89%
12.8B
3.8B
6.86% -11.90%
17.13
3.39
8.58% 129.81%
MID-CAP
5.8B
107.9M
23.06% 120.60%
-10.63
48.09
54.84% -28.31%
5.1B
524.1M
-18.99% -52.96%
-12.22
9.73
394.93% 39.61%
3.7B
251.0M
12.53% -1.35%
-12.4
14.64
73.58% -86.73%
3.1B
240.7M
5.66% -32.59%
-6.6
12.77
-1.03% -213.43%
2.5B
813.8M
-13.11% -34.57%
-1.4K
3.01
56.43% 98.83%
SMALL-CAP
2.0B
996.6M
260.65% 85.68%
-5.07
2.03
-26.66% 65.49%
1.9B
411.3M
5.34% 30.65%
29.69
4.7
60.38% -34.49%
489.5M
881.7K
11.38% 343.80%
-14.5
481.06
-77.61% 33.36%
330.9M
4.9M
32.47% 47.80%
-2.65
67.99
-54.97% 48.23%
15.7M
2.1M
-6.67% 89.09%
-0.68
7.61
-13.45% 69.54%

Titan Pharmaceuticals Inc News

Latest updates
Defense World10 hours ago

Titan Pharmaceuticals Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In Thousands)
Income Statement (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue---3.0083.0098.0012195.001501921352644456821,4451,0181,2491,126211947502945
Costs and Expenses---2,4711,6711,795-2,7382,5922,7312,6242,1722,7703,3143,9012,2142,8673,101-4,9634,8305,3845,230
Operating Expenses-1,063---1,795---------------5,230
  S&GA Expenses-100.0%-1,0382,0471,2291,2341,2891,8061,6181,3221,6489791,0351,3271,8561,3271,2231,289-3,9353,0233,2313,082
  R&D Expenses-100.0%-4874244425611,4439329741,4099761,1931,6461,8771,5738871,6441,812-2901,6191,9071,844
Interest Expenses-23.5%13.0017.00------------97.0096.00102104109110109
Net Income32.2%-1,060-1,564-744-1,586-1,675-2,566-2,638-2,462-2,540-2,540-1,915-1,680-2,641-3,085-4,932-4,641-5,584-3,941-2,803-5,197-4,517
Net Income Margin11.0%-26.92*-30.27*-21.58*-21.35*-20.15*-18.31*-17.80*-12.76*-8.37*-5.75*-3.29*-3.44*-3.48*-3.77*-------
Free Cashflow66.5%-618-1,845-2,246-1,117-1,904-1,584-1,878-1,772-2,969-1,086-2,262-1,949-2,625-4,570-------
Balance Sheet
(In Thousands)
Balance Sheet
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets-17.8%6,6468,0869,9998122,1684,0586,2768,31910,3187,9949,63711,50713,8248,0878,0189,76213,2629,5225,3046,76111,440
  Current Assets-17.5%6,6118,0189,8994981,7853,6035,7477,7139,6337,2298,84510,63013,1897,3286,6498,69012,1468,3083,9465,49310,089
    Cash Equivalents-8.9%6,1596,7608,0961051,1362,9374,4506,4208,1386,3327,4189,68011,6295,4134,0735,4988,0385,2239212,2925,909
  Inventory-----1061064604692932931291292183281,0739691,0645631,3091,3171,246
  Net PPE-40.0%3.005.006.009.001812242693173684204685245636181,161799780817752754782
Liabilities-61.3%5591,4441,8661,8462,4802,6952,7262,6522,4362,8562,1412,7603,8444,5558,9158,2027,9868,0897,9647,3328,385
  Current Liabilities-61.3%5591,4441,8661,8462,4472,6302,6302,5242,2782,6691,9252,5163,7564,2235,8774,8574,4103,6003,4824,3424,761
  Long Term Debt-------------88.003323,0383,3453,5004,0193,8722,6983,242
    LT Debt, Current-------------5723272,0821,624667--1,3331,227
    LT Debt, Non Current-------------88.003323,0383,3453,5004,0193,8722,6983,242
Shareholder's Equity-8.4%6,0876,6428,133--3121,3633,5505,6677,8825,1387,4968,7479,9803,532-1,5605,2761,433--3,055
  Retained Earnings-0.3%-392,890-391,830-390,266-389,522-387,936-386,261-383,695-381,057-378,595-376,055-373,515-371,600-369,920-367,279-364,194-359,262-354,621-349,037-345,096-342,293-337,096
  Additional Paid-In Capital0.1%398,975398,470398,383388,473387,609387,623387,230386,709386,465381,183381,001380,337379,890370,804363,180360,725359,804350,468342,419341,708340,138
Shares Outstanding17.0%91478215,016751751751731685602496493493464357-------
Float--------7,300---25,600---29,700---17,300-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations66.7%-613-1,840-2,241-1,112-1,899-1,579-1,873-1,767-2,964-1,081-2,262-1,931-2,625-4,561-3,447-3,983-5,212-3,663-3,325-4,149-4,308
  Share Based Compensation-100.0%-48.00411264290-91.0027,00027.002531469.004472483.009.0079.00-84.00-42.00128350136
Cashflow From Investing-100.0%-504--------5.00--18.00--9.00-444-57.00-30.00-112-61.00-39.00-44.00
Cashflow From Financing--------3.004,981---8,8415,9102,4661,5008,0578,0772,015571605
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

TTNP Income Statement

2024-03-31
CONDENSED STATEMENTS OF OPERATIONS (Unaudited) - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Revenues:  
Total revenues$ 98
Operating expenses:  
Research and development561
General and administrative1,0631,234
Total operating expenses1,0631,795
Loss from operations(1,063)(1,697)
Other income:  
Interest income, net122
Other income, net2
Other income, net322
Net loss$ (1,060)$ (1,675)
Basic net loss per common share$ (1.24)$ (2.23)
Diluted net loss per common share$ (1.24)$ (2.23)
Weighted average shares used in computing basic net loss per common share853751
Weighted average shares used in computing diluted net loss per common share853751
Grant [Member]  
Revenues:  
Total revenues$ 98

TTNP Balance Sheet

2024-03-31
CONDENSED BALANCE SHEETS (Unaudited) - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 6,159$ 6,760
Restricted cash13
Receivables13446
Notes receivable1,000
Prepaid expenses and other current assets318199
Total current assets6,6118,018
Property and equipment, net35
Operating lease right-of-use asset, net3263
Total assets6,6468,086
Current liabilities:  
Accounts payable371348
Note payable to related party500
Other accrued liabilities155519
Operating lease liability, current3365
Deferred grant revenue12
Total current liabilities5591,444
Total liabilities5591,444
Stockholders’ equity (deficit):  
Preferred stock, at amounts paid in, $0.001 par value per share; 5,000,000 shares authorized, 950,000 shares issued and outstanding at March 31, 2024 and December 31, 2023.11
Common stock, at amounts paid in, $0.001 par value per share; 225,000,000 shares authorized, 914,234 and 781,503 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively.11
Additional paid-in capital398,975398,470
Accumulated deficit(392,890)(391,830)
Total stockholders’ equity6,0876,642
Total liabilities and stockholders’ equity$ 6,646$ 8,086
TTNP
Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in the United States, Canada, and the European Union. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including HIV preventative therapeutic and a contraceptive from a single ProNeura implant for women and adolescent girls. The company was incorporated in 1992 and is based in South San Francisco, California.
 CEO
 WEBSITEtitanpharm.com
 INDUSTRYBiotechnology
 EMPLOYEES4

Titan Pharmaceuticals Inc Frequently Asked Questions


What is the ticker symbol for Titan Pharmaceuticals Inc? What does TTNP stand for in stocks?

TTNP is the stock ticker symbol of Titan Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Titan Pharmaceuticals Inc (TTNP)?

As of Thu May 16 2024, market cap of Titan Pharmaceuticals Inc is 5.92 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of TTNP stock?

You can check TTNP's fair value in chart for subscribers.

What is the fair value of TTNP stock?

You can check TTNP's fair value in chart for subscribers. The fair value of Titan Pharmaceuticals Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Titan Pharmaceuticals Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for TTNP so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Titan Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether TTNP is over valued or under valued. Whether Titan Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact Titan Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for TTNP.

What is Titan Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 16 2024, TTNP's PE ratio (Price to Earnings) is -1.2 and Price to Sales (PS) ratio is 32.2. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. TTNP PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Titan Pharmaceuticals Inc's stock?

In the past 10 years, Titan Pharmaceuticals Inc has provided -0.531 (multiply by 100 for percentage) rate of return.